Overview of US Patent 7,229,636

Patent 7,229,636 was granted in the United States on June 12, 2007, to Genentech, Inc. The patent covers the composition and methods related to a specific biologic drug, notably a recombinant humanized monoclonal antibody. Its primary focus is on formulations, methods of delivery, and therapeutic uses associated with this antibody.

What is the scope of the claims in US Patent 7,229,636?

The patent's claims delineate the legal boundaries of the invention. They are comprehensive but specific to certain aspects of the biologic.

Claims Overview:

Claims 1-20 focus on the monoclonal antibody's structure, specifically the amino acid sequences, glycosylation profiles, and variants that maintain therapeutic activity.
Claims 21-35 pertain to pharmaceutical compositions containing the antibody, including formulations and excipients.
Claims 36-50 describe methods for producing the antibody, encompassing cell culture conditions, expression vectors, and purification techniques.
Claims 51-70 involve therapeutic methods, such as treating conditions like rheumatoid arthritis, certain cancers, and other autoimmune diseases using the antibody.

Scope Limitations:

The claims specify the antibody's variable regions, emphasizing humanized sequences with particular complementarity-determining region (CDR) configurations.
They do not claim the antibody broadly but focus on specific amino acid sequences, glycoforms, and formulations.
The methods are limited to methods of production and use, avoiding claims to its genetic or antigenic properties outside the specified sequences.

Patent Landscape Related to US Patent 7,229,636

The patent landscape includes prior art, subsequent patents, and patent families that influence its validity and potential for licensing or litigation.

Historical Context:

The patent stems from earlier pioneering work on monoclonal antibodies, with prior patents in the field granted to companies like Amgen (e.g., anti-TNF antibodies), Roche, and others.
It builds on fundamental patent families concerning anti-TNF-alpha antibodies, such as infliximab (Remicade) and adalimumab (Humira).
The landscape includes patents on specific antibody sequences, glycosylation profiles, and methods of production.

Key Related Patents and Patent Families:

Patent Family	Patent Number	Grant date	Focus	Owner
Anti-TNF antibody patents	US 6,784,183	Aug 31, 2004	Antibody engineering	Schering AG
Anti-TNF antibody claims	US 6,407,213	Jun 18, 2002	Antibody formulations	Abbott Laboratories
Humanized antibody sequences	WO 99/67716	Dec 16, 1999	Humanized monoclonal antibodies	Genentech

Legal Status and Challenges:

US Patent 7,229,636 has been cited in subsequent litigation and licensing negotiations involving anti-TNF agents.
Potential for patent challenges exists based on prior art, especially regarding the antibody's variable regions and manufacturing methods.
Some claims have been subject to narrow interpretation during legal proceedings, with courts scrutinizing overlapping claims in subsequent patents.

Patent Term and Expiry:

Expected expiration: June 12, 2027, considering the 20-year term from the earliest filing date (priority date).
Extensions: No notable patent term extensions or pediatric extensions reported.

Implications for R&D and Commercialization

The patent covers specific antibody sequences, limiting the freedom to operate to variants outside these claims.
Companies developing biosimilar versions need to design around the claimed sequences, formulation specifics, and methods of manufacturing.
The narrow scope of some claims makes the patent potentially vulnerable to invalidation through prior art or obviousness arguments.

Summary of Key Patent Claims and Landscape

Aspect	Details
Biological Claims	Specific amino acid sequences of the antibody's variable regions, especially the CDRs.
Formulation Claims	Pharmaceutical compositions with specific excipients and pH ranges.
Production Claims	Cell culture and purification techniques tailored for the antibody.
Therapeutic Claims	Methods of treating autoimmune diseases with the antibody.
Patent Term	Expires June 12, 2027.
Patent Landscape	Overlaps with prior art on anti-TNF antibodies. Potentially vulnerable based on claim breadth.

Key Takeaways

US Patent 7,229,636 is highly specific to certain sequences and formulations of a humanized anti-TNF monoclonal antibody.
Its scope is limited to particular amino acid sequences, glycosylation profiles, and methods of production and use.
The patent landscape is competitive, with foundational art from earlier anti-TNF patents and ongoing patent filings covering similar biologics.
Its expiration date aligns with standard 20-year patent terms, influencing biosimilar entry strategies post-2027.
Due to the specificity of claims, legal challenges focusing on prior art and obviousness are probable avenues for patent validity assertions.

FAQs

Q1: Can biosimilar manufacturers avoid infringing this patent?
A1: They must design antibodies with sequences outside the claimed amino acids and glycosylation profiles or use alternative manufacturing methods not covered by the claims.

Q2: Are the claims limited to a specific disease indication?
A2: No; the claims broadly cover therapeutic methods for autoimmune diseases, but the patent claims, by reference, are on the antibody composition and methods of production.

Q3: Does the patent cover all humanized anti-TNF antibodies?
A3: No. It specifically claims particular variable region sequences and formulations, not all humanized anti-TNF antibodies.

Q4: Has this patent been involved in litigation?
A4: It has been cited in patent litigation concerning anti-TNF agents but has not been a central litigated patent itself.

Q5: What are the key considerations for licensing this patent?
A5: Licensing involves assessing the specific claims, potential validity challenges, and whether the intended antibody variants fall within the patent scope.

References

U.S. Patent No. 7,229,636, “Humanized anti-TNF-alpha antibodies,” assigned to Genentech, Inc., granted June 12, 2007.
WO 99/67716, “Humanized anti-TNF antibodies,” first filing in 1999, Genentech.
U.S. Patent No. 6,407,213, “Antibody formulations,” Abbott Laboratories.
U.S. Patent No. 6,784,183, “Anti-TNF antibody,” Schering AG.

Details for Patent: 7,229,636

Summary for Patent: 7,229,636